Fusion Protein Stimulates Stem Cell Differentiation for Leukopenia Recovery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bone marrow inhibition, such as chemotherapy and radiotherapy, lead to adverse reactions like leukopenia and compromised hematopoietic function, with existing colony stimulating factors promoting none-self-renewal hematopoietic progenitor cells, depleting bone marrow reserves and potentially increasing tumor recurrence.
Innovation Solution
A fusion protein with specific amino acid sequences (SEQ ID NO: 2 or SEQ ID NO: 4) is used to stimulate the differentiation of bone marrow mesenchymal stem cells to hematopoietic stem/progenitor cells, promoting the proliferation of granulocytic hematopoietic progenitor cells, thereby enhancing hematopoiesis and preventing leukopenia without stimulating tumor cell proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If colony stimulating factors (G-CSF, GM-CSF) are used to promote the proliferation of granulocytic hematopoietic progenitor cells, then the recovery of white blood cells and neutrophils is expedited, but the depletion of hematopoietic progenitor cells occurs and long-term recovery is compromised
Solution Approach 1:
The fusion protein acts as an intermediary that indirectly promotes granulocyte recovery by stimulating mesenchymal stem cells to differentiate into hematopoietic progenitor cells, rather than directly stimulating granulocytic progenitor cells. This mediator approach preserves the long-term hematopoietic reserve while achieving rapid recovery.
Solution Approach 2:
The fusion protein performs preliminary action by expanding the hematopoietic progenitor cell pool before chemotherapy-induced depletion occurs. By pre-stimulating mesenchymal stem cell differentiation, sufficient progenitor cells are available to withstand chemotherapy and enable rapid recovery without depleting reserves.
2Speed
If colony stimulating factors are used to promote hematopoietic progenitor cell proliferation, then white blood cell recovery is accelerated, but tumor cell proliferation may be increased
Solution Approach 1:
The fusion protein exhibits local quality by specifically targeting mesenchymal stem cells for differentiation into hematopoietic progenitors, while having selective action that does not stimulate tumor cells. This localized and selective stimulation achieves therapeutic benefit without promoting tumor growth.
3Reliability
If colony stimulating factors are used repeatedly to maintain normal treatment course, then hematopoietic function is maintained, but the instability of CSF causes dramatic white blood cell count changes
Solution Approach 1:
The fusion protein enables self-service by stimulating the bone marrow's intrinsic capacity to produce hematopoietic progenitors through mesenchymal stem cell differentiation. This activates the body's own regenerative mechanisms, providing stable and sustained hematopoietic support without the dramatic fluctuations associated with repeated exogenous CSF administration.
Data Source
AI summary
Disclosed is the use of a fusion protein in drugs for stimulating differentiation of bone marrow mesenchymal stem cells to hematopoietic stem/progenitor cells, or drugs for proliferation of granulocyte hematopoietic progenitor cells. The fusion protein has a sequence as shown in SEQ ID NO: 2 or SEQ ID NO: 4. The drugs can be used for the prevention and/or treatment of (i) hematopoietic dysfunction caused by chemotherapy, (ii) hematopoietic dysfunction caused by radiotherapy, or (iii) leukopenia.